{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:38:58Z","timestamp":1794865138371,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Aceruloplasminemia is a rare genetic iron overload disorder, characterized by progressive neurological manifestations. The effects of iron chelation on neurological outcomes have only been described in case studies, and are inconsistent. Aggregated case reports were analyzed to help delineate the disease-modifying potential of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data on clinical manifestations, treatment and neurological outcomes of treatment were collected from three neurologically symptomatic Dutch patients, who received deferiprone with phlebotomy as a new therapeutic approach, and combined with other published cases. Neurological outcomes of treatment were compared between patients starting treatment when neurologically symptomatic and patients without neurological manifestations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Therapeutic approaches for aceruloplasminemia have been described in 48 patients worldwide, including our three patients. Initiation of treatment in a presymptomatic stage of the disease delayed the estimated onset of neurological manifestations by 10\u2009years (median age 61\u2009years, SE 5.0 vs. median age 51\u2009years, SE 0.6, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). Although in 11\/20 neurologically symptomatic patients neurological manifestations remained stable or improved during treatment, these patients were treated significantly shorter than patients who deteriorated neurologically (median 6\u2009months vs. median 43\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u20090.016). Combined iron chelation therapy with deferiprone and phlebotomy for up to 34\u2009months could be safely performed in our patients without symptomatic anemia (2\/3), but did not prevent further neurological deterioration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Early initiation of iron chelation therapy seems to postpone the onset of neurological manifestations in aceruloplasminemia. Publication bias and significant differences in duration of treatment should be considered when interpreting reported treatment outcomes in neurologically symptomatic patients. Based on theoretical grounds and the observed long-term safety and tolerability in our study, we recommend iron chelation therapy with deferiprone in combination with phlebotomy for aceruloplasminemia patients without symptomatic anemia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-020-01385-w","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T19:02:56Z","timestamp":1587841376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports"],"prefix":"10.1186","volume":"15","author":[{"given":"Lena H. P.","family":"Vroegindeweij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnita J. W.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. Paul","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke G.","family":"Langendonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"key":"1385_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/neup.12149","volume":"35","author":"H Miyajima","year":"2015","unstructured":"Miyajima H. Aceruloplasminemia. Neuropathology. 2015;35:83\u201390.","journal-title":"Neuropathology"},{"key":"1385_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3389\/fnins.2018.00903","volume":"12","author":"A Piperno","year":"2018","unstructured":"Piperno A, Alessio M. Aceruloplasminemia: waiting for an efficient therapy. Front Neurosci. 2018;12:903.","journal-title":"Front Neurosci"},{"key":"1385_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jtemb.2016.03.010","volume":"38","author":"P Dusek","year":"2016","unstructured":"Dusek P, Schneider SA, Aaseth J. Iron chelation in the treatment of neurodegenerative diseases. J Trace Elem Med Biol. 2016;38:81\u201392.","journal-title":"J Trace Elem Med Biol"},{"key":"1385_CR4","doi-asserted-by":"publisher","first-page":"20185","DOI":"10.1074\/jbc.272.32.20185","volume":"272","author":"BN Patel","year":"1997","unstructured":"Patel BN, David S. A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. J Biol Chem. 1997;272:20185\u201390.","journal-title":"J Biol Chem"},{"key":"1385_CR5","doi-asserted-by":"publisher","first-page":"27144","DOI":"10.1074\/jbc.M301988200","volume":"278","author":"SY Jeong","year":"2003","unstructured":"Jeong SY, David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem. 2003;278:27144\u20138.","journal-title":"J Biol Chem"},{"key":"1385_CR6","first-page":"19","volume":"28","author":"RW Evans","year":"1992","unstructured":"Evans RW, Sharma M, Ogwand W, Patel KJ, Bartlett AN, Kontoghiorghes GJ. The effect of alpha-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo. Drugs Today. 1992;28:19\u201323.","journal-title":"Drugs Today"},{"key":"1385_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1136\/gut.2003.030429","volume":"53","author":"R Mariani","year":"2004","unstructured":"Mariani R, Arosio C, Pelucchi S, Grisoli M, Piga A, Trombini P, et al. Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. Gut. 2004;53:756\u20138.","journal-title":"Gut"},{"key":"1385_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/bjh.13401","volume":"171","author":"M Badat","year":"2015","unstructured":"Badat M, Kaya B, Telfer P. Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia. Br J Haematol. 2015;171:430\u20132.","journal-title":"Br J Haematol"},{"key":"1385_CR9","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/bjh.13512","volume":"170","author":"E Vlachodimitropoulou Koumoutsea","year":"2015","unstructured":"Vlachodimitropoulou Koumoutsea E, Garbowski M, Porter J. Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization. Br J Haematol. 2015;170:874\u201383.","journal-title":"Br J Haematol"},{"key":"1385_CR10","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMra1800219","volume":"379","author":"RC Hider","year":"2018","unstructured":"Hider RC, Hoffbrand AV. The role of Deferiprone in Iron chelation. N Engl J Med. 2018;379:2140\u201350.","journal-title":"N Engl J Med"},{"key":"1385_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13023-019-1202-6","volume":"14","author":"M Sampayo-Cordero","year":"2019","unstructured":"Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Malfettone A, Perez-Garcia J, Llombart-Cussac A, et al. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases. Orphanet J Rare Dis. 2019;14:230.","journal-title":"Orphanet J Rare Dis"},{"key":"1385_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ymgme.2018.01.002","volume":"123","author":"M Sampayo-Cordero","year":"2018","unstructured":"Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Molto-Abad M, Munoz-Delgado C, Perez-Lopez J. Agreement between the results of meta-analyses from case reports and from clinical studies regarding the efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age: an example of case reports meta-analyses as an useful tool for evidence-based medicine in rare diseases. Mol Genet Metab. 2018;123:69\u201375.","journal-title":"Mol Genet Metab"},{"key":"1385_CR13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/dme.12712","volume":"32","author":"LH Vroegindeweij","year":"2015","unstructured":"Vroegindeweij LH, van der Beek EH, Boon AJ, Hoogendoorn M, Kievit JA, Wilson JH, et al. Aceruloplasminemia presents as type 1 diabetes in non-obese adults: a detailed case series. Diabet Med. 2015;32:993\u20131000.","journal-title":"Diabet Med"},{"key":"1385_CR14","doi-asserted-by":"publisher","first-page":"46632","DOI":"10.1074\/jbc.M206246200","volume":"277","author":"NE Hellman","year":"2002","unstructured":"Hellman NE, Kono S, Mancini GM, Hoogeboom AJ, De Jong GJ, Gitlin JD. Mechanisms of copper incorporation into human ceruloplasmin. J Biol Chem. 2002;277:46632\u20138.","journal-title":"J Biol Chem"},{"key":"1385_CR15","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/hep.26719","volume":"59","author":"M Kerkhof","year":"2014","unstructured":"Kerkhof M, Honkoop P. Never forget aceruloplasminemia in case of highly suggestive Wilson's disease score. Hepatology. 2014;59:1645\u20137.","journal-title":"Hepatology"},{"key":"1385_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.parkreldis.2016.12.010","volume":"36","author":"LH Vroegindeweij","year":"2017","unstructured":"Vroegindeweij LH, Langendonk JG, Langeveld M, Hoogendoorn M, Kievit AJA, Di Raimondo D, et al. New insights in the neurological phenotype of aceruloplasminemia in Caucasian patients. Parkinsonism Relat Disord. 2017;36:33\u201340.","journal-title":"Parkinsonism Relat Disord"},{"key":"1385_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.parkreldis.2018.02.036","volume":"51","author":"S Pelucchi","year":"2018","unstructured":"Pelucchi S, Mariani R, Ravasi G, Pelloni I, Marano M, Tremolizzo L, et al. Phenotypic heterogeneity in seven Italian cases of aceruloplasminemia. Parkinsonism Relat Disord. 2018;51:36\u201342.","journal-title":"Parkinsonism Relat Disord"},{"key":"1385_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.bcmd.2015.12.011","volume":"57","author":"S Pelucchi","year":"2016","unstructured":"Pelucchi S, Pelloni I, Arosio C, Mariani R, Piperno A. Does aceruloplasminemia modulate iron phenotype in thalassemia intermedia? Blood Cells Mol Dis. 2016;57:112\u20134.","journal-title":"Blood Cells Mol Dis"},{"key":"1385_CR19","first-page":"316","volume":"68","author":"C Bethlehem","year":"2010","unstructured":"Bethlehem C, van Harten B, Hoogendoorn M. Central nervous system involvement in a rare genetic iron overload disorder. Neth J Med. 2010;68:316\u20138.","journal-title":"Neth J Med"},{"key":"1385_CR20","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.4045\/tidsskr.14.1115","volume":"135","author":"MH Bjork","year":"2015","unstructured":"Bjork MH, Gjerde IO, Tzoulis C, Ulvik RJ, Bindoff LA. A man in his 50s with high ferritin levels and increasing cognitive impairment. Tidsskr Nor Laegeforen. 2015;135:1369\u201372.","journal-title":"Tidsskr Nor Laegeforen"},{"key":"1385_CR21","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1212\/WNL.0000000000001956","volume":"85","author":"F Bove","year":"2015","unstructured":"Bove F, Fasano A. Iron chelation therapy to prevent the manifestations of aceruloplasminemia. Neurology. 2015;85:1085\u20136.","journal-title":"Neurology"},{"key":"1385_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/imj.13309","volume":"47","author":"GL Calder","year":"2017","unstructured":"Calder GL, Lee MH, Sachithanandan N, Bell S, Zeimer H, MacIsaac RJ. Aceruloplasminaemia: a disorder of diabetes and neurodegeneration. Intern Med J. 2017;47:115\u20138.","journal-title":"Intern Med J"},{"key":"1385_CR23","doi-asserted-by":"publisher","unstructured":"Doyle A, Rusli F, Bhathal P. Aceruloplasminaemia: a rare but important cause of iron overload. BMJ Case Rep. 2015:bcr2014207541. https:\/\/doi.org\/10.1136\/bcr-2014-207541.","DOI":"10.1136\/bcr-2014-207541"},{"key":"1385_CR24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/mds.21938","volume":"23","author":"A Fasano","year":"2008","unstructured":"Fasano A, Colosimo C, Miyajima H, Tonali PA, Re TJ, Bentivoglio AR. Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability. Mov Disord. 2008;23:751\u20135.","journal-title":"Mov Disord"},{"key":"1385_CR25","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jhep.2010.04.039","volume":"53","author":"A Finkenstedt","year":"2010","unstructured":"Finkenstedt A, Wolf E, Hofner E, Gasser BI, Bosch S, Bakry R, et al. Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J Hepatol. 2010;53:1101\u20137.","journal-title":"J Hepatol"},{"key":"1385_CR26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/jnnp.2003.017434","volume":"75","author":"I Haemers","year":"2004","unstructured":"Haemers I, Kono S, Goldman S, Gitlin JD, Pandolfo M. Clinical, molecular, and PET study of a case of aceruloplasminaemia presenting with focal cranial dyskinesia. J Neurol Neurosurg Psychiatry. 2004;75:334\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1385_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003594","volume":"95","author":"M Hayashida","year":"2016","unstructured":"Hayashida M, Hashioka S, Miki H, Nagahama M, Wake R, Miyaoka T, et al. Aceruloplasminemia with psychomotor excitement and neurological sign was improved by minocycline (case report). Medicine (Baltimore). 2016;95:e3594.","journal-title":"Medicine (Baltimore)"},{"key":"1385_CR28","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/gut.47.6.858","volume":"47","author":"NE Hellman","year":"2000","unstructured":"Hellman NE, Schaefer M, Gehrke S, Stegen P, Hoffman WJ, Gitlin JD, et al. Hepatic iron overload in aceruloplasminaemia. Gut. 2000;47:858\u201360.","journal-title":"Gut"},{"key":"1385_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jns.2010.08.019","volume":"298","author":"A Hida","year":"2010","unstructured":"Hida A, Kowa H, Iwata A, Tanaka M, Kwak S, Tsuji S. Aceruloplasminemia in a Japanese woman with a novel mutation of CP gene: clinical presentations and analysis of genetic and molecular pathogenesis. J Neurol Sci. 2010;298:136\u20139.","journal-title":"J Neurol Sci"},{"key":"1385_CR30","doi-asserted-by":"publisher","first-page":"894","DOI":"10.7326\/L17-0621","volume":"168","author":"MC Hines Jr","year":"2018","unstructured":"Hines MC Jr, Bonkovsky HL, Rudnick SR, Mhoon JT. Peripheral neuropathy and the Ceruloplasmin gene. Ann Intern Med. 2018;168:894\u20135.","journal-title":"Ann Intern Med"},{"key":"1385_CR31","first-page":"303","volume":"47","author":"U Lindner","year":"2015","unstructured":"Lindner U, Schuppan D, Schleithoff L, Habeck JO, Grodde T, Kirchhof K, et al. Aceruloplasminaemia: a family with a novel mutation and long-term therapy with deferasirox. Horm Metab Res. 2015;47:303\u20138.","journal-title":"Horm Metab Res"},{"key":"1385_CR32","first-page":"663","volume":"87","author":"JI Logan","year":"1994","unstructured":"Logan JI, Harveyson KB, Wisdom GB, Hughes AE, Archbold GP. Hereditary caeruloplasmin deficiency, dementia and diabetes mellitus. Qjm. 1994;87:663\u201370.","journal-title":"Qjm"},{"key":"1385_CR33","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0168-8278(02)00042-9","volume":"36","author":"O Loreal","year":"2002","unstructured":"Loreal O, Turlin B, Pigeon C, Moisan A, Ropert M, Morice P, et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol. 2002;36:851\u20136.","journal-title":"J Hepatol"},{"key":"1385_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jns.2014.02.014","volume":"339","author":"A Matsushima","year":"2014","unstructured":"Matsushima A, Yoshida T, Yoshida K, Ohara S, Toyoshima Y, Kakita A, et al. Superficial siderosis associated with aceruloplasminemia. Case report. J Neurol Sci. 2014;339:231\u20134.","journal-title":"J Neurol Sci"},{"key":"1385_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1212\/WNL.37.5.761","volume":"37","author":"H Miyajima","year":"1987","unstructured":"Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology. 1987;37:761\u20137.","journal-title":"Neurology"},{"key":"1385_CR36","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/ana.410410318","volume":"41","author":"H Miyajima","year":"1997","unstructured":"Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin JD. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol. 1997;41:404\u20137.","journal-title":"Ann Neurol"},{"key":"1385_CR37","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2169\/internalmedicine.50.5108","volume":"50","author":"M Ogimoto","year":"2011","unstructured":"Ogimoto M, Anzai K, Takenoshita H, Kogawa K, Akehi Y, Yoshida R, et al. Criteria for early identification of aceruloplasminemia. Intern Med. 2011;50:1415\u20138.","journal-title":"Intern Med"},{"key":"1385_CR38","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/mds.23797","volume":"26","author":"PL Pan","year":"2011","unstructured":"Pan PL, Tang HH, Chen Q, Song W, Shang HF. Desferrioxamine treatment of aceruloplasminemia: long-term follow-up. Mov Disord. 2011;26:2142\u20134.","journal-title":"Mov Disord"},{"key":"1385_CR39","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jhep.2005.02.013","volume":"42","author":"F Perez-Aguilar","year":"2005","unstructured":"Perez-Aguilar F, Burguera JA, Benlloch S, Berenguer M, Rayon JM. Aceruloplasminemia in an asymptomatic patient with a new mutation. Diagnosis and family genetic analysis. J Hepatol. 2005;42:947\u20139.","journal-title":"J Hepatol"},{"key":"1385_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10072-016-2756-x","volume":"38","author":"L Poli","year":"2017","unstructured":"Poli L, Alberici A, Buzzi P, Marchina E, Lanari A, Arosio C, et al. Is aceruloplasminemia treatable? Combining iron chelation and fresh-frozen plasma treatment. Neurol Sci. 2017;38:357\u201360.","journal-title":"Neurol Sci"},{"key":"1385_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.parkreldis.2018.03.003","volume":"51","author":"GM Riboldi","year":"2018","unstructured":"Riboldi GM, Anstett K, Jain R, Lau H, Swope D. Aceruloplasminemia and putaminal cavitation. Parkinsonism Relat Disord. 2018;51:121\u20133.","journal-title":"Parkinsonism Relat Disord"},{"key":"1385_CR42","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5581\/1516-8484.20110104","volume":"33","author":"R Roberti Mdo","year":"2011","unstructured":"Roberti Mdo R, Borges Filho HM, Goncalves CH, Lima FL. Aceruloplasminemia: a rare disease - diagnosis and treatment of two cases. Rev Bras Hematol Hemoter. 2011;33:389\u201392.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"1385_CR43","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/cge.12145","volume":"85","author":"M Rusticeanu","year":"2014","unstructured":"Rusticeanu M, Zimmer V, Schleithoff L, Wonney K, Viera J, Zimmer A, et al. Novel ceruloplasmin mutation causing aceruloplasminemia with hepatic iron overload and diabetes without neurological symptoms. Clin Genet. 2014;85:300\u20131.","journal-title":"Clin Genet"},{"key":"1385_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp.2007.120568","volume":"79","author":"FM Skidmore","year":"2008","unstructured":"Skidmore FM, Drago V, Foster P, Schmalfuss IM, Heilman KM, Streiff RR. Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation. J Neurol Neurosurg Psychiatry. 2008;79:467\u201370.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1385_CR45","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2169\/internalmedicine.52.0102","volume":"52","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y, Yoshida K, Aburakawa Y, Kuroda K, Kimura T, Terada T, et al. Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation. Intern Med. 2013;52:1527\u201330.","journal-title":"Intern Med"},{"key":"1385_CR46","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/hepr.12292","volume":"44","author":"M Tai","year":"2014","unstructured":"Tai M, Matsuhashi N, Ichii O, Suzuki T, Ejiri Y, Kono S, et al. Case of presymptomatic aceruloplasminemia treated with deferasirox. Hepatol Res. 2014;44:1253\u20138.","journal-title":"Hepatol Res"},{"key":"1385_CR47","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2169\/internalmedicine.9855-17","volume":"57","author":"M Watanabe","year":"2018","unstructured":"Watanabe M, Ohyama K, Suzuki M, Nosaki Y, Hara T, Iwai K, et al. Aceruloplasminemia with abnormal compound heterozygous mutations developed neurological dysfunction during phlebotomy therapy. Intern Med. 2018;57:2713\u20138.","journal-title":"Intern Med"},{"key":"1385_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000008091","volume":"42","author":"M Yonekawa","year":"1999","unstructured":"Yonekawa M, Okabe T, Asamoto Y, Ohta M. A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma. Eur Neurol. 1999;42:157\u201362.","journal-title":"Eur Neurol"},{"key":"1385_CR49","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.410370515","volume":"37","author":"H Morita","year":"1995","unstructured":"Morita H, Ikeda S, Yamamoto K, Morita S, Yoshida K, Nomoto S, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol. 1995;37:646\u201356.","journal-title":"Ann Neurol"},{"key":"1385_CR50","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1474-4422(19)30142-5","volume":"18","author":"T Klopstock","year":"2019","unstructured":"Klopstock T, Tricta F, Neumayr L, Karin I, Zorzi G, Fradette C, et al. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol. 2019;18:631\u201342.","journal-title":"Lancet Neurol"},{"key":"1385_CR51","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23:60\u20133.","journal-title":"BMJ Evid Based Med"},{"key":"1385_CR52","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/1756-0500-7-264","volume":"7","author":"T Nissen","year":"2014","unstructured":"Nissen T, Wynn R. The clinical case report: a review of its merits and limitations. BMC Res Notes. 2014;7:264.","journal-title":"BMC Res Notes"},{"key":"1385_CR53","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jhep.2014.03.037","volume":"61","author":"A Cucchetti","year":"2014","unstructured":"Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, Ciccarese F, et al. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol. 2014;61:333\u201341.","journal-title":"J Hepatol"},{"key":"1385_CR54","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/ajg.2017.185","volume":"112","author":"L Zakko","year":"2017","unstructured":"Zakko L, Visrodia K, Wang KK, Iyer PG. Editorial: the effect of Bias on estimation of improved survival after diagnosis of Barrett's esophagus. Am J Gastroenterol. 2017;112:1265\u20136.","journal-title":"Am J Gastroenterol"},{"key":"1385_CR55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/aje\/kwn120","volume":"168","author":"SW Duffy","year":"2008","unstructured":"Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, Warwick J, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol. 2008;168:98\u2013104.","journal-title":"Am J Epidemiol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01385-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01385-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01385-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T23:46:28Z","timestamp":1619307988000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01385-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1385"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01385-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Medical Ethics Review Board Erasmus MC (approval number: MEC-2013-280).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}